AstraZeneca Etcamah SERENA-4 trial results, disclosed by the company on 11 September 2026 as inside information under EU and UK market abuse rules, showed that the Phase III study did not reach statistical significance on its primary endpoint of progression-free survival (PFS), even though investigators recorded a numerical improvement favoring the oral selective estrogen receptor degrader (SERD) combination. The trial tested Etcamah (camizestrant) in the upfront first-line setting for advanced, hormone receptor (HR)-positive, HER2-negative breast cancer, a population that had not previously received any systemic treatment for advanced disease.
The Phase III trial compared Etcamah plus palbociclib, a cyclin-dependent kinase (CDK) 4/6 inhibitor, against the established pairing of the aromatase inhibitor anastrozole plus palbociclib. Enrollment covered adult patients newly diagnosed with Stage IV de novo disease or with recurrence from earlier-stage breast cancer, none of whom had received prior systemic therapy for metastatic disease. The design effectively asked whether Etcamah could displace aromatase inhibitors as frontline endocrine therapy, rather than serve only as a later switch option after resistance emerges.
Susan Galbraith, Executive Vice President of Oncology Haematology Research and Development at AstraZeneca, said the company was disappointed by the outcome but that it sharpens focus on maximizing the number of patients who already benefit from Etcamah based on the separate SERENA-6 trial. She reinforced the importance of ESR1 mutation testing for patients on first-line therapy and said AstraZeneca remains confident in Etcamah’s long-term potential in earlier breast cancer settings as its broader development programme advances.
AstraZeneca reported that the safety profile of the Etcamah-palbociclib combination in SERENA-4 was consistent with the known safety profile of each medicine individually, and that no new safety concerns were identified. Detailed efficacy figures, hazard ratios, and safety tabulations have not yet been released; the company said additional data would be shared in due course, leaving a transparency gap that oncologists and investors will be watching closely.
AstraZeneca Etcamah SERENA-4 Trial Design and Patient Population
The AstraZeneca Etcamah SERENA-4 study is registered on ClinicalTrials.gov as NCT04711252, a Phase III, double-blind, randomized trial. The table below summarizes the core design parameters as disclosed in AstraZeneca’s press release.
| Trial Parameter | Reported Detail |
|---|---|
| Trial name | SERENA-4 |
| Registry ID | NCT04711252 |
| Phase | Phase III, double-blind, randomized |
| Investigational arm | Etcamah (camizestrant) + palbociclib |
| Comparator arm | Anastrozole (aromatase inhibitor) + palbociclib |
| Patient population | ER-positive, HER2-negative advanced breast cancer, 1st-line, no prior systemic therapy for advanced disease |
| Enrollment | 1,371 adult patients |
| Disease stages included | Stage IV de novo or recurrent disease |
| Prior adjuvant therapy requirement | At least 24 months of adjuvant endocrine therapy (AI or tamoxifen) for recurrent cases, with at least 12 months elapsed since the last adjuvant AI dose without progression |
| Result date disclosed | 11 September 2026 |
Patients with recurrence from early-stage disease were required to have completed at least 24 months of standard adjuvant endocrine therapy, either an aromatase inhibitor or tamoxifen, with a minimum 12-month gap since their last adjuvant aromatase inhibitor dose and no progression during that treatment. This eligibility structure, central to the AstraZeneca Etcamah SERENA-4 protocol, was designed to isolate a genuinely treatment-naive advanced-disease population rather than patients who had merely paused therapy.
The primary endpoint of the AstraZeneca Etcamah SERENA-4 trial was investigator-assessed PFS, while secondary endpoints included overall survival (OS), PFS2 (time to second progression), and health-related quality of life (HRQOL) measures. AstraZeneca has not yet disclosed the numerical PFS values, hazard ratio, or confidence interval for either arm, describing the result only as a “numerical improvement” that fell short of statistical significance.
The broader clinical backdrop underscores why a frontline win in the AstraZeneca Etcamah SERENA-4 trial mattered. Breast cancer remains the second most common cancer worldwide and a leading cause of cancer death, with more than two million new diagnoses and over 690,000 deaths recorded globally in 2024. HR-positive disease, marked by estrogen or progesterone receptor expression, accounts for roughly 70% of breast tumors, and more than 97% of HR-positive tumors are also ER-positive. Only about 30% of patients with metastatic or progressed disease are expected to survive five years, which is the population SERENA-4 targeted.
AstraZeneca Etcamah SERENA-4 Safety and Efficacy Data at a Glance
Because AstraZeneca has withheld granular AstraZeneca Etcamah SERENA-4 efficacy figures pending a future data presentation, the table below documents exactly what has and has not been disclosed, flagging undisclosed metrics rather than estimating them.
| Endpoint / Metric | Status as Disclosed by AstraZeneca |
|---|---|
| Primary endpoint (investigator-assessed PFS) | Did not meet statistical significance; numerical improvement observed |
| Exact PFS figures / hazard ratio | Not disclosed |
| Overall survival (OS) | Secondary endpoint; data not disclosed |
| PFS2 | Secondary endpoint; data not disclosed |
| Health-related quality of life (HRQOL) | Secondary endpoint; data not disclosed |
| Safety profile | Consistent with known safety profile of Etcamah and palbociclib individually; no new safety signals |
| Full data release | Company states data “will be shared in due course” |
AstraZeneca Etcamah SERENA-4 Trial’s Context Within an Already-Approved Indication
Despite the AstraZeneca Etcamah SERENA-4 miss, Etcamah is not a novel or unapproved molecule. In combination with a CDK4/6 inhibitor, palbociclib, ribociclib, or abemaciclib, it is already approved in the US, EU, Japan and other countries for adult patients with HR-positive (or ER-positive), HER2-negative locally advanced or metastatic breast cancer upon detection or emergence of an ESR1 mutation during first-line endocrine-based therapy. That approval rests on the separate SERENA-6 Phase III trial, a different study design in which patients switch therapy after ESR1 mutation detection rather than starting on Etcamah from diagnosis, as SERENA-4 tested.
Etcamah is a next-generation oral selective estrogen receptor degrader and complete ER antagonist, dosed once daily as a 75mg tablet when combined with a CDK4/6 inhibitor. The distinction between the AstraZeneca Etcamah SERENA-4 and SERENA-6 trial designs matters clinically: SERENA-6 identifies resistance as it emerges via ESR1 mutation testing and switches therapy proactively, while SERENA-4 attempted to establish Etcamah as an upfront replacement for aromatase inhibitors before resistance develops. The SERENA-4 result suggests that, at least for PFS by investigator assessment, an unselected frontline population does not show a statistically significant benefit from making that switch immediately.
AstraZeneca’s broader oral SERD programme in earlier disease stages remains active regardless of the SERENA-4 result. The CAMBRIA-1 and CAMBRIA-2 Phase III trials, together encompassing approximately 10,000 patients, are evaluating Etcamah as a monotherapy, in combination with CDK4/6 inhibitors, and following CDK4/6 inhibitor treatment in the adjuvant, early breast cancer setting for patients at intermediate and high risk of recurrence. AstraZeneca has framed early breast cancer as an important opportunity that is unaffected by the AstraZeneca Etcamah SERENA-4 first-line metastatic result.
AstraZeneca Etcamah SERENA-4 Trial Sits Within a Wider Breast Cancer Pipeline Strategy
AstraZeneca’s breast cancer portfolio extends well beyond Etcamah, and the AstraZeneca Etcamah SERENA-4 setback does not alter the company’s stated ambition to eliminate breast cancer as a cause of death. The company continues to develop Enhertu (trastuzumab deruxtecan), a HER2-directed antibody-drug conjugate partnered with Daiichi Sankyo, for HER2-positive, HER2-low, and HER2-ultralow metastatic disease, alongside exploration of earlier treatment lines. In HR-positive disease, foundational medicines Faslodex (fulvestrant) and Zoladex (goserelin) remain in use, while Truqap (capivasertib), a first-in-class AKT inhibitor, and Datroway (datopotamab deruxtecan), a TROP-2-directed ADC also partnered with Daiichi Sankyo, round out the HR-positive strategy alongside Etcamah.
For triple-negative breast cancer specifically, AstraZeneca and Daiichi Sankyo are evaluating Datroway alone and combined with the immunotherapy Imfinzi. Separately, AstraZeneca is testing saruparib, a PARP1 inhibitor, in combination with either Etcamah or endocrine therapy in BRCA-mutated, HR-positive, HER2-negative advanced breast cancer, illustrating how the company is layering combination strategies around its existing approved medicines even as individual trials like SERENA-4 fall short of their primary goal.
